Dishman Carbogen Amcis Ltd has announced the successful completion of a scheduled US FDA inspection at its Naroda facility in Ahmedabad. The inspection, which was planned from June 9 to June 13, 2025, was concluded early on June 12, 2025, without any observations or issuance of Form 483.
This outcome confirms that no compliance concerns were identified by the US health regulator, reaffirming the company’s strong commitment to global regulatory standards and quality systems.
With this development, Dishman Carbogen Amcis’ facilities at Naroda and Bavla in India, along with its group facilities in Switzerland and the Netherlands, remain in good standing with the US FDA. This reinforces the company’s reputation as a reliable global player in the pharmaceutical contract development and manufacturing organization (CDMO) space.
The company expressed its appreciation to all employees involved and reiterated its dedication to maintaining the highest standards in quality and compliance.
This successful audit outcome is expected to boost customer confidence and support future business growth, especially in regulated markets like the United States.
Ahmedabad Plane Crash